Replimune Group Inc

Contributing Author

Recent Articles by Replimune Group Inc

Jun-06	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REPL GlobeNewswire
Jun-01	Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting REPL GlobeNewswire
May-29	Replimune to Present at the 2025 Jefferies Global Healthcare Conference REPL GlobeNewswire
May-22	Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update REPL GlobeNewswire
May-16	Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day REPL GlobeNewswire
May-09	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REPL GlobeNewswire